In conclusion, these results demonstrated that plasma exosomal MUC5B and SELL could serve as potential biomarkers for diagnosing LC patients with BM, and plasma exosomal APOH was a novel potential diagnostic biomarker of LC patients with LM. Here, MUC5B is linked to laryngotracheoesophageal cleft.